Toxoplasmosis is caused by Toxoplasma gondii, an apicomplexan parasite that is able to
infect any nucleated cell in any warm-blooded animal. Toxoplasma gondii infects around 2 …

As an emerging novel drug carrier, nanoparticles provide a promising way for effective
treatment of parasitic diseases by overcoming the shortcomings of low bioavailability, poor …

Background Although, approximately 30% of the world's population is estimated to be
infected with Toxoplasma gondii (T. gondii) with serious manifestations in …

The novel formula of spiramycin/propolis loaded chitosan (CS)/alginate (Alg) nanoparticles
(NPs) was assessed for Toxoplasma gondii (T. gondii) treatment in comparison with the …

Antibiotic pollution is becoming increasingly severe due to its extensive use. The potential
application of the anaerobic ammonium oxidation (anammox) process in the treatment of …

Toxoplasma gondii (T. gondii) is a highly prevalent parasite that has no gold standard
treatment due to the poor action or the numerous side effects. Focused sulfonamide-1, 2, 3 …

Cyclosporiasis is a ubiquitous infection caused by an obligate intracellular protozoan
parasite known as Cyclospora cayetanensis (C. cayetanensis). The disease is characterized …

The goal was to scrutinize niosomes as potential carriers for enhanced efficacy of
norfloxacin against Toxoplasma gondii RH strain. This was assessed in vitro and in vivo …

The control of toxoplasmosis, a rampant one health disease, has been focussed on
conventional antitoxoplasmic agents with their adverse outcomes, including serious side …

Despite being the initial choice for treating toxoplasmosis, sulfadiazine and pyrimethamine
have limited effectiveness in eliminating the infection and were linked to a variety of adverse …